

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
PA44-33288A
APPLICATION NO.
10/585,455
APPLICANT
AZRIA ET AL.
FILING DATE
April 5, 2006

Group

U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE |
|---------------------|-----------------|------|------|-------|----------|-------------|
| | AA | | | | | |
| | AB | | | | | |
| | AC | | | | | |
| | AD | | | | | |
| | AE | | | | | |
| | AF | | | | | |
| | AG | | | | | |
| | AH | | | | | |
| | AI | | | | | |
| | AJ | | | | | |
| | AK | | | | | |
| | AL | | | | | |

FOREIGN PATENT DOCUMENTS

| | DOCUMENT NUMBER | DATE | OFFICE | CLASS | SUBCLASS | TRANSLATION | |
|--|-----------------|----------|--------|-------|----------|--------------------------|--------------------------|
| | | | | | | YES | NO |
| | AM 00/59863 | 10/12/00 | WO | | | <input type="checkbox"/> | <input type="checkbox"/> |
| | AN 05 345729 | 12/27/93 | JP | | | <input type="checkbox"/> | <input type="checkbox"/> |
| | AO | | | | | <input type="checkbox"/> | <input type="checkbox"/> |
| | AP | | | | | <input type="checkbox"/> | <input type="checkbox"/> |
| | AQ | | | | | <input type="checkbox"/> | <input type="checkbox"/> |

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

| | |
|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| AR | Mongiorgi et al., "Influence of Calcitonin Treatment on the Bone Structure and Mineral Content in Osteoarthritis", Bollettino Societa Italiana Biologia Sperimentale, Vol. 68, No. 2, pp. 85-89 (1992). |
| AS | Gospodinoff et al., "Calcitonin in Treatment of Coxarthrosis", Clinica Terapeutica, Vol. 110, No. 2, pp. 129-133 (1984). |
| AT | Consoli et al., "Calcitonin in Rheumatologic Osteoporosis Aspects and Prelimin Evaluation of Pathophysiology and Clinical Features", Clinica Terapeutica, Vol. 118, No. 1, pp. 37-47 (1986). |

EXAMINER

/Xiaozhen Xie/

DATE CONSIDERED

02/11/2009

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /X.Z.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Group

EXAMINER
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

| | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| BA | Guggi et al., "In Vitro Evaluation of Polymeric Excipients Protecting Calcitonin Against Degradation by Intestinal Serine Proteases", International Journal of Pharmaceutics, Vol. 252, No. 1-2, pp. 187-196 (2003); Database Medline 'Online', Abstract Database Accession No. NLM12550794. |
| BB | Smethurst et al., "Combined Therapy with Ascorbic Acid and Calcitonin for the Relief of Bone Pain in Paget's Disease", ACTA Vitaminologica et Enzymologica, Vol. 3, No. 1, pp. 8-11 (1981). |
| BC | Lee et al., "Oral Delivery of Salmon Calcitonin", Advanced Drug Delivery Reviews, Vol. 42, No. 3, pp. 225-238 (2000). |
| BD | |
| BE | |
| BF | |
| BG | |
| BH | |
| BI | |
| BJ | |
| BK | |
| BL | |
| BM | |
| BN | |

EXAMINER

/Xiaozhen Xie/

DATE CONSIDERED

02/11/2009

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609. Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /X.Z./